1. Ginsenoside Rg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulation of EGFR/PI3K/Akt signaling pathway
   Jin Jiang et al, 2017, Biomedicine & Pharmacotherapy CrossRef
2. AKT2 drives cancer progression and is negatively modulated by miR-124 in human lung adenocarcinoma
   Ting Liu et al, 2020, Respiratory Research CrossRef
3. Kinome-Wide Profiling Identifies Human WNK3 as a Target of Cajanin Stilbene Acid from Cajanus cajan (L.) Millsp.
   Nadire Özenver et al, 2022, International Journal of Molecular Sciences CrossRef
4. Vav1 Down-Modulates Akt2 Expression in Cells from Pancreatic Ductal Adenocarcinoma: Nuclear Vav1 as a Potential Regulator of Akt Related Malignancy in Pancreatic Cancer
   Silvia Grassilli et al, 2020, Biomedicines CrossRef
5. Functional characteristics of DNA N6-methyladenine modification based on long-read sequencing in pancreatic cancer
   Dianshuang Zhou et al, 2024, Briefings in Functional Genomics CrossRef
6. Knockdown of the DJ-1 (PARK7) gene sensitizes pancreatic cancer to erlotinib inhibition
   Xiangyi He et al, 2021, Molecular Therapy - Oncolytics CrossRef
7. MUL1 E3 ligase regulates the antitumor effects of metformin in chemoresistant ovarian cancer cells via AKT degradation
   Junwoo Lee et al, 2019, International Journal of Oncology CrossRef
8. Functional Characteristics of DNA N6-Methyladenine Modification Based on ONT Sequencing in Pancreatic Cancer
   Dianshuang Zhou et al, SSRN Electronic Journal CrossRef
9. Trimodal Mixed Mode Chromatography That Enables Efficient Offline Two-Dimensional Peptide Fractionation for Proteome Analysis
   Peng Yu et al, 2017, Analytical Chemistry CrossRef
10. MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma
    Ankit P. Jain et al, 2019, Scientific Reports CrossRef
11. Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer
    Sara Redaelli et al, 2018, Cancer Research CrossRef
12. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1
    Zhe-bin Dong et al, 2022, Cell Death & Disease CrossRef
13. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
    Yixuan Ma et al, 2022, International Journal of Molecular Sciences CrossRef
14. Impact of posttranslational modifications in pancreatic carcinogenesis and treatments
    Nianhong Chen et al, 2021, Cancer and Metastasis Reviews CrossRef